QORO Intelligence was founded by a veteran quality and pharmacovigilance professional who spent 15+ years watching drug safety teams drown in manual processes. AE Connect is the result of over 2 years of development, shaped by strategic advisory from PV experts across the industry.
Pharmacovigilance is one of the most critical functions in drug development, and one of the most underserved by technology. Legacy systems were built for large pharmaceutical operations with dedicated IT teams and seven-figure budgets.
QORO Intelligence exists to change that. After more than 2 years of development, informed by hands-on experience and strategic input from PV experts across pharma, biotech, and CROs, we built AE Connect from the ground up for lean drug safety teams.
AE Connect is our flagship product: an AI-powered adverse event reporting platform designed specifically for emerging biotech companies that need enterprise-grade PV infrastructure without enterprise-grade complexity or cost.
We build every feature with regulatory requirements as the foundation, not an afterthought. 21 CFR Part 11, ICH E2B, and GxP principles are baked into the architecture, not bolted on later.
Every hour spent on manual data entry is an hour not spent on safety signal detection. We obsess over reducing the administrative burden so drug safety professionals can focus on what matters.
From our pricing, published openly on our website, to our AI recommendations, which always show their reasoning. We believe trust is built through visibility, not black boxes.
Our beta cohort isn't just an early access program, it's a product partnership. Beta clients shape the roadmap, test new features first, and get direct access to the founding team.
Every AI recommendation in AE Connect is a suggestion, not a decision. The medical reviewer is always in control. We use AI to eliminate the tedious, not to automate the critical.
We are not building a scaled-down version of an enterprise system. AE Connect is purpose-built for companies with 20–500 employees, the workflows, the pricing, and the support model.
When a biotech company gets its first drug approved, the regulatory obligations don't pause while the team figures out their PV infrastructure. The 15-day clock starts ticking immediately.
Most emerging biotechs face an impossible choice: pay $80,000–$250,000+ for a legacy system built for Big Pharma, or manage adverse events manually with spreadsheets and shared inboxes.
A 3-person drug safety team processing 500 cases per year at 3.5 hours per case spends over 1,750 hours annually, nearly one full-time equivalent, on intake and triage alone.
$131K+ in annual laborFDA Warning Letters for late IND safety reports are public, permanent, and damaging. Manual tracking systems fail at scale, particularly during safety signal clusters when volume spikes suddenly.
FDA enforcement increasingArgus, Veeva Vault Safety, and Oracle's PV suite are priced for global pharmaceutical companies with dedicated IT teams. Emerging biotech pays enterprise prices for features they'll never use.
AE Connect costs up to 75% lessDaman brings over 15 years of experience in quality assurance, regulatory compliance, and pharmacovigilance across pharmaceutical and biotech companies. He has led quality systems and PV operations across multiple therapeutic areas, oncology, neurodegenerative diseases, infectious diseases, working with companies ranging from early-stage biotech to established pharma.
Having spent his career on the front lines of drug safety, Daman saw firsthand how manual processes, disconnected systems, and enterprise-priced software create an impossible burden for small PV teams. He founded QORO Intelligence to solve that problem, building AE Connect as the modern, AI-powered alternative that emerging biotech companies deserve.
AE Connect has been over 2 years in the making, developed with strategic advisory from pharmacovigilance experts across different segments of the industry, including safety operations, regulatory affairs, and clinical development, ensuring the platform reflects real-world PV workflows, not theoretical ones.
AE Connect was developed with strategic input from pharmacovigilance experts across different parts of the industry, safety operations, regulatory affairs, clinical development, and life sciences technology. We are continuing to expand our advisory network.
Former VP Drug Safety at a top-20 biotech. Deep expertise in pharmacovigilance operations, signal detection, and regulatory submissions.
Founder of a successful regulated life sciences SaaS company. Experience taking a GxP-compliant software product from zero to Series A.
Senior regulatory affairs professional with experience navigating FDA and EMA pharmacovigilance requirements across multiple therapeutic areas.
Book a 20-minute discovery call. We'll talk through your current PV setup and show you exactly how AE Connect fits.